Adverse effects include visual disturbances, dry mouth, cough, nausea, eyelid edema and lacrimation.
Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. |
| Hydrocodone | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Levocabastine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Levocabastine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. |
| Mirtazapine | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. |
| Orphenadrine | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. |
| Pramipexole | Levocabastine may increase the sedative activities of Pramipexole. |
| Ropinirole | Levocabastine may increase the sedative activities of Ropinirole. |
| Rotigotine | Levocabastine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Levocabastine. |
| Suvorexant | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. |
| Thalidomide | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Levocabastine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Levocabastine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Levocabastine. |
| Ethanol | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Levocabastine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Levocabastine is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Levocabastine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Levocabastine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Levocabastine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Levocabastine is combined with Alaproclate. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Citalopram. |
| Escitalopram | The risk or severity of adverse effects can be increased when Levocabastine is combined with Escitalopram. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Levocabastine. |
| Olanzapine | The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Levocabastine. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Levocabastine. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Levocabastine. |
| Nortriptyline | The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Levocabastine. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Levocabastine. |
| Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Levocabastine. |
| Nicardipine | The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Levocabastine. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Levocabastine. |
| Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Levocabastine. |
| Tolterodine | The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Levocabastine. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Levocabastine. |
| Diphenhydramine | The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Levocabastine. |
| Doxepin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Doxepin. |
| Desipramine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Desipramine. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Aripiprazole. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Chlorprothixene. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Solifenacin. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Trimebutine. |
| Dosulepin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dosulepin. |
| Zopiclone | The risk or severity of adverse effects can be increased when Levocabastine is combined with Zopiclone. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Leuprolide. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Goserelin. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Azithromycin. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Moxifloxacin. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ranolazine. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Sulfisoxazole. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Amitriptyline. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Diltiazem. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Clozapine. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Sulpiride. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Nimodipine. |
| Promazine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Promazine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Prochlorperazine. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Imipramine. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Chlorpromazine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levocabastine. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ciprofloxacin. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Fluorouracil. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Perflutren. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Cinnarizine. |
| Atropine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Atropine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Chloroquine. |
| Efavirenz | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Efavirenz. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Adenosine. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Pentamidine. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Gadobenic acid. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Carbinoxamine. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dolasetron. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Roxithromycin. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Nalidixic acid. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Cinoxacin. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Loperamide. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Granisetron. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ondansetron. |